1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Further Iclaprim Analyses Ahead Of Crucial Months For Motif Bio

 
• By John Davis

A 3 May meeting with the FDA is likely to be crucial for the future commercialization strategy for the biotech’s precision-targeted antibacterial.

Data
The FDA wants to see additional data. • Source: Shutterstock

The under-pressure UK biotech, Motif Bio PLC, has presented more clinical data on its lead Gram-positive targeted investigational antibacterial, iclaprim, as it prepares for a meeting with US regulators on 3 May to discuss the recent turning down of the product’s US marketing submission, announced in February.

In a post hoc evaluation of pooled data from two Phase III studies, REVIVE-1 and REVIVE-2, fixed doses of iclaprim...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.